Prevalence Of, Associations With, and Prognostic Role of Anemia in Heart Failure Across the Ejection Fraction Spectrum
Overview
Authors
Affiliations
Background: The role of anemia in heart failure with mid-range and preserved ejection fraction (HFmrEF, EF 40-49% and HFpEF, EF ≥50%) is unknown. We aimed to compare prevalence of, associations with, and prognostic role of anemia in HF across the EF spectrum.
Methods: In patients from the Swedish HF Registry, we assessed the associations between clinical characteristics and anemia (hemoglobin <120 g/L in women and <130 g/L in men) by multivariable logistic regression, and between anemia, composite of all-cause death and HF hospitalization and all-cause death alone by multivariable Cox regression.
Results: Of 49,985 patients with HF (anemia = 34%), 23% had HFpEF (anemia = 41%), 21% had HFmrEF (anemia = 35%) and 55% had HFpEF (anemia = 32%). Higher EF was independently associated with higher likelihood of concomitant anemia. Important predictors of anemia across the EF spectrum were male sex, older age, worse New York Heart Association class and renal function, lower systolic blood pressure, higher N-Terminal B-type natriuretic peptides levels, diabetes, valvular disease and in-patient status. Anemia had adjusted hazard ratios (95% CI) for mortality or HF hospitalization 1.24 (1.18-1.30) in HFpEF, 1.26 (1.19-1.34) in HFmrEF and 1.14 (1.10-1.19) in HFrEF; pEF = 0.003; and for mortality 1.28 (1.20-1.36) in HFpEF, 1.21 (1.13-1.29) in HFmrEF, and 1.30 (1.24-1.35) in HFrEF; pEF = 0.22.
Conclusions: In this nation-wide registry, prevalence of anemia was higher in HFpEF vs. HFmrEF vs. HFrEF, but was associated with a similarly increased risk of death across the EF spectrum, with greater risk of death or HF hospitalization in HFpEF and HFmrEF vs. HFrEF.
Mechanisms of exercise intolerance in hear-t failure with preserved ejection fraction (HFpEF).
Pecchia B, Samuel R, Shah V, Newman E, Gibson G Heart Fail Rev. 2025; .
PMID: 40080287 DOI: 10.1007/s10741-025-10504-3.
Steinke P, Schupp T, Kuhn L, Abumayyaleh M, Weidner K, Bertsch T J Clin Med. 2024; 13(20).
PMID: 39458040 PMC: 11508757. DOI: 10.3390/jcm13206088.
Development and Challenges of Pre-Heart Failure with Preserved Ejection Fraction.
Dong G Rev Cardiovasc Med. 2024; 24(9):274.
PMID: 39076392 PMC: 11270127. DOI: 10.31083/j.rcm2409274.
Shahim A, Donal E, Hage C, Oger E, Savarese G, Persson H ESC Heart Fail. 2024; 11(6):3572-3583.
PMID: 39075721 PMC: 11631285. DOI: 10.1002/ehf2.14928.
Exploring Sirtuins: New Frontiers in Managing Heart Failure with Preserved Ejection Fraction.
Lu Y, Li Y, Xie Y, Bu J, Yuan R, Zhang X Int J Mol Sci. 2024; 25(14).
PMID: 39062982 PMC: 11277469. DOI: 10.3390/ijms25147740.